Maternal Passive Immunity and Dengue Hemorrhagic Fever in Infants.


Journal

Bulletin of mathematical biology
ISSN: 1522-9602
Titre abrégé: Bull Math Biol
Pays: United States
ID NLM: 0401404

Informations de publication

Date de publication:
28 01 2020
Historique:
received: 03 06 2019
accepted: 10 01 2020
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 24 3 2021
Statut: epublish

Résumé

Dengue hemorrhagic fever (DHF) can occur in primary dengue virus infection of infants [Formula: see text] year of age. To understand the presumed role of maternal dengue-specific antibodies received until birth in the development of this primary DHF in infants, we investigated a mathematical model based on a system of nonlinear ordinary differential equations that mimics cells, virus and antibodies interactions. The neutralization and enhancement activities of maternal antibodies against the virus are represented by a function derived from experimental data and knowledge from the medical literature. The analytic study of the model shows the existence of two equilibriums, a disease-free equilibrium and an endemic one. We performed the asymptotic stability analysis for these two equilibriums. The local asymptotic stability of the endemic equilibrium (DHF equilibrium) corresponds to the occurrence of DHF. Numerical results are also presented in order to illustrate the mathematical analysis performed, highlighting the most important parameters that drive model dynamics. We defined the age at which DHF occurs as the time when the infection takes off that means at the inflection point of the curve of infected cell population. We showed that this age corresponds to the one at which maximum enhancing activity for dengue infection appears. This critical time for the occurrence of DHF is calculated from the model to be approximately 2 months after the time for maternal dengue neutralizing antibodies to degrade below a protective level, which corresponds to what is observed in the experimental data from the literature.

Identifiants

pubmed: 31993759
doi: 10.1007/s11538-020-00699-x
pii: 10.1007/s11538-020-00699-x
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24

Auteurs

Mostafa Adimy (M)

Inria, Université de Lyon, Université Lyon 1, 43 Bd. du 11 novembre 1918, 69200, Villeurbanne Cedex, France.

Paulo F A Mancera (PFA)

São Paulo State University (UNESP), Rua Prof. Dr. Antônio Celso Wagner Zanin, 250, District of Rubião Junior, Botucatu, SP, 18618-689, Brazil.

Diego S Rodrigues (DS)

School of Technology, University of Campinas (UNICAMP), Rua Paschoal Marmo, 1888, Limeira, SP, 13484-332, Brazil.

Fernando L P Santos (FLP)

São Paulo State University (UNESP), Rua Prof. Dr. Antônio Celso Wagner Zanin, 250, District of Rubião Junior, Botucatu, SP, 18618-689, Brazil.

Cláudia P Ferreira (CP)

São Paulo State University (UNESP), Rua Prof. Dr. Antônio Celso Wagner Zanin, 250, District of Rubião Junior, Botucatu, SP, 18618-689, Brazil. claudia.pio@unesp.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH